OncoMatch/Clinical Trials/NCT05562518
GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.
Is NCT05562518 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Estrogen and dehydroepiandrosterone for vulvovaginal atrophy.
Treatment: Estrogen · dehydroepiandrosterone · Estrogen + probiotics · Moisturizer — In this prospective active-controlled randomized trial the investigators will assess for the first time ever the different local treatments of vulvovaginal atrophy in breast cancer patients on endocrine therapy. These patients are currently inadequately treated based on ignorance of possible treatment modalities and stigmatization of vulvovaginal atrophy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Prior therapy
Must have received: endocrine therapy — current
current endocrine therapy (AI or SERM)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify